Strategies using the immune system for therapy of brain tumors.
Phase II immunotherapy and gene therapy studies should be pursued because of encouraging results in many phase I studies. Future testing in this field may consider modifications of some of the above-mentioned combined strategies. For instance, in the immunization and adoptive transfer studies performed by Holladay et al and by Plautz et al, the systemic adoptive transfer could be altered to intratumoral placements of effector cells. This permutation may be more efficacious because local adoptive immunotherapy approaches involve placement of effector cells where they are needed. Additionally, new avenues of gene therapy are being explored that may offer added beneficial effects for immunization, local or systemic adoptive immunotherapy, or combined chemotherapy and adoptive immunotherapy of tumors. With new genetic tools, such as microarray analyses, SEREX, and creation of cDNA libraries from tumor cells, significant progress in the treatment of neoplasms in the immunologically privileged brain should be forthcoming.
Virasch
N
N
Department of Immunology, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Kruse
C A
CA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015295:Antigens, Tumor-Associated, Carbohydrate; D001932:Brain Neoplasms / Q000276:immunology* / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D016207:Cytokines / Q000235:genetics / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008024:Ligands; D008214:Lymphocytes / Q000276:immunology; D014611:Vaccination
D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate; D019496:Cancer Vaccines; D016207:Cytokines; D008024:Ligands